TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21241447
Drug: Laughter therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laughter therapy
Study: 7698890
Drug: high‐dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: high‐dose methylprednisolone
Study: 7698890
Drug: low‐dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: low‐dose methylprednisolone
Study: 3661613
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g)
Study: 3661613
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g) with indomethacin (50 mg) pretreatment
Study: 3661613
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg) pretreatment
Study: 29106749
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment simultaneous to periodontal treatment
Study: 29106749
Drug: Cause-related periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cause-related periodontal treatment before orthodontic treatment (Control)
Study: 22416849
Drug: Rilpivirine (RPV;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilpivirine (RPV; TMC278) 25 mg once a day
Study: 22416849
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) 600 mg once a day
Study: 1447645
Drug: DTP‐Ac vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP‐Ac vaccine
Study: 26667034
Drug: Cannabis (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis (450 μg/kg THC)
Study: 24106872
Drug: Cocaine HCl
Normalized name: cocaine HCl
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine HCl (300 mg)
Study: 23106987
Drug: Unimanual constraint‐induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unimanual constraint‐induced movement therapy (CIMT)
Study: 18046973
Drug: Zofenopril 30
Normalized name: zofenopril 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril 30 mg once daily (titration 60 mg od)
Study: 18046973
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg once daily (titration 100 mg od)
Study: 18046973
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events related to study medications
Study: 12522468
Drug: perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: perindopril 4 mg
Study: 10547552
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (50 mg every other day)
Study: 8697725
Drug: Gel-DAT
Normalized name: Otic Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel-DAT
Study: 6203312
Drug: Anthralin treatment
Normalized name: Anthralin
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthralin treatment once or twice a week after healing
Study: 6203312
Drug: Anthralin treatment
Normalized name: Anthralin
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthralin treatment combined with UV irradiation
Study: 6203312
Drug: Anthralin treatment
Normalized name: Anthralin
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthralin treatment
Study: 29513699
Drug: No pills
Normalized name: No Doz Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pills at all (Control)
Study: 25269854
Drug: Olopatadine HCl
Normalized name: olopatadine HCl
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine HCl ophthalmic solution 0.1%
Study: 25269854
Drug: Epinastine HCl
Normalized name: epinastine HCl
DrugBank: Epinastine (DB00751)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epinastine HCl ophthalmic solution 0.05%
Study: 16236859
Drug: Aminophylline 225
Normalized name: aminophylline 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 225 mg bid po for 8 weeks (group 1)
Study: 16236859
Drug: Aminophylline 225
Normalized name: aminophylline 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 225 mg bid po for 8 weeks (group 2)
Study: 16236859
Drug: Aminophylline 225
Normalized name: aminophylline 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 225 mg bid po for 8 weeks (both groups)
Study: 9933750
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil (EPO) 2 g/day for 6 weeks
Study: 9933750
Drug: Linoleic acid
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linoleic acid (LA) 2 g/day for 6 weeks
Study: 2186867
Drug: Pharmacologic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic therapies (e.g., low-dose diuretics such as Chlorthalidone, 12.5 or 25 mg per day)
Study: 23131078
Drug: Pharmacologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic therapy
Study: 2186867
Drug: Low-dose diuretics
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose diuretics
Study: 2186867
Drug: Other agents
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other agents (beta-blockers, reserpine, ACE inhibitors, calcium channel blockers)
Study: 355960
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous carbenicillin (administered preoperatively and continued for 24 hours)
Study: 355960
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic antibiotics (control)
Study: 25887344
Drug: Primaquine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine combined with dihydroartemisinin-piperaquine (three different single doses)
Study: 20004499
Drug: Estrogen treatment
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen treatment for 12 weeks
Study: 15589857
Drug: HMR 3339
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMR 3339 (10 mg)
Study: 15589857
Drug: HMR 3339
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMR 3339 (50 mg)
Study: 15589857
Drug: HMR 3339
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMR 3339 (2.5 mg)
Study: 7915625
Drug: Chronic beta‐adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic beta‐adrenergic blocking therapy (study group)
Study: 7915625
Drug: No beta‐blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta‐blocking therapy (control group)
Study: 8815556
Drug: Mepartricin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepartricin at a dose of 150,000 U, administered once a day in the evening for 6 months
Study: 6524275
Drug: Intramuscular oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular oxycodone and/or metamizol (IM)
Study: 6524275
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 4 mg (EM)
Study: 6524275
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of fentanyl 0.54‐0.99 micrograms min‐1 + on-demand boluses of 7.2‐13.5 micrograms (ODAC)
Study: 27129139
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy performed twice a week
Study: 25112009
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia by lidocaine (1%) combined with midazolam (0.04 mg/kg) intravenous sedation
Study: 19618315
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/d combined with aspirin 100 mg/d
Study: 19618315
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of aspirin 100 mg/d
Study: 19332730
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg
Study: 12106935
Drug: Acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (600 mg orally twice daily) with 0.45% saline intravenously (group A)
Study: 2206783
Drug: Enalapril 10‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10‐40 mg once daily
Study: 2206783
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard 10‐40 mg twice daily
Study: 2206783
Drug: Hydrochlorothiazide 12.5‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5‐50 mg once daily (added for inadequate responders)
Study: 27611077
Drug: Brincidofovir 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brincidofovir 200 mg loading dose on day 0, followed by 100 mg on days 3, 7, 10, and 14 (bodyweight-adjusted for patients <50 kg).
Study: 21926599
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion for blood glucose control to 80-110 mg/dL
Study: 21926599
Drug: Conventional glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucose management (insulin administered only when glucose levels rose above 215 mg/dL)
Study: 15310081
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 to 100 mg/d
Study: 15310081
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 to 160 mg/d
Study: 7811043
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (528 mg, 30 ml of Pepto-Bismol)
Study: 7811043
Drug: Ciprofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (750 mg)
Study: 3290706
Drug: CR4-Sinemet (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR4-Sinemet (twice daily)
Study: 25382074
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab injection (IVBI) 1.25 mg at baseline and pro re nata based on ME presence; follow-up for 12 months.
Study: 25382074
Drug: Subthreshold grid
Normalized name: MINERAL OIL 100 g in 100 mL TOPICAL LIQUID [THE GRID]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subthreshold grid laser treatment (SGLT) administered once; follow-up for 12 months.
Study: 23441791
Drug: Er,Cr:YSGG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er,Cr:YSGG laser assisted pocket therapy (ELAPT)
Study: 23441791
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (ELAPT and OFD)
Study: 21855969
Drug: Propiverine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine treatment
Study: 14603093
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of benzathine penicillin, azithromycin, and cefixime
Study: 14603093
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of cefixime and 3 doses of azithromycin given biweekly
Study: 11164425
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg bezafibrate once daily for 6 weeks
Study: 9342067
Drug: GM-CSF (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (300 microg subcutaneously daily for 1 week, then 150 microg subcutaneously two times weekly for 11 weeks)
Study: 2870732
Drug: ICI 141,292
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 141,292 200 mg
Study: 2870732
Drug: ICI 141,292
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 141,292 400 mg
Study: 25721770
Drug: Ciprofloxacin-containing sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin-containing sequential therapy
Study: 25721770
Drug: Clarithromycin-containing sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin-containing sequential therapy
Study: 23715567
Drug: MAGE-A3 immunotherapy
Normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGE-A3 immunotherapy (n = 122)
Study: 20860413
Drug: Colesevelam plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam plus low-dose statin or niacin
Study: 20860413
Drug: Colesevelam (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam (1.5 g/day to 3.75 g/day)
Study: 15940147
Drug: Beta-methasone-17-valerate (BMV)
Normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta-methasone-17-valerate (BMV) cream 0.1%
Study: 15940147
Drug: Matching vehicle
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching vehicle cream
Study: 9088806
Drug: OLITA program
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLITA program (Outpatient Long‐term Intensive Therapy for Alcoholics)
Study: 1534047
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily in the morning for seven days
Study: 1534047
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily in the evening for seven days
Study: 1534047
Drug: Lansoprazole (morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (morning and evening dosing)
Study: 30736761
Drug: Non-operative shoulder
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative shoulder exercise treatment (not specified dosage or duration)
Study: 30736761
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not receiving non-operative shoulder treatment)
Study: 25241755
Drug: T-PEMF once
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-PEMF once daily (active dose in the morning and sham in the afternoon)
Study: 25241755
Drug: T-PEMF twice
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T-PEMF twice daily (active dose both morning and afternoon)
Study: 18931219
Drug: NMBAS-guided rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMBAS-guided rocuronium administration
Study: 11707843
Drug: EPOCH chemotherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPOCH chemotherapy (etoposide/doxorubicin/vincristine/cyclophosphamide/prednisone)
Study: 19204798
Drug: EPOCH chemotherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPOCH chemotherapy
Study: 9203934
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily for four weeks
Study: 7692755
Drug: Therapy for
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy for recurrent malignant neoplasia (pure yolk sac tumor or teratoma with yolk sac elements)
Study: 3114808
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg alprazolam PO daily as 2 mg bid
Study: 3114808
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg qid
Study: 3114808
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg each hour
Study: 29766330
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment alone (Er group)
Study: 29766330
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with Nd:YAG and Er:YAG lasers (NdErNd group)
Study: 28162931
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group (IG) - Staged multicomponent tailored behavioral interventions (e.g., electronic monitoring feedback, motivational interviewing)
Study: 26241254
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 10 mg administered 30-60 minutes before surgical abortion.
Study: 26241254
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 30-60 minutes before surgical abortion.
Study: 20803856
Drug: 5 ml*h(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml*h(‐1) ropivacaine 0.2% (study group, n = 21)
Study: 20803856
Drug: 5 ml*h(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml*h(‐1) saline (control group, n = 21)
Study: 18763292
Drug: Total parental
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parental nutrition (TPN) in combination with operation
Study: 11086664
Drug: granisetron 2
Normalized name: granisetron 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: granisetron 2 mg
Study: 8828422
Drug: Continuous hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous hormone replacement therapy (first 6 months)
Study: 8828422
Drug: Suspension of
Normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension of hormone replacement therapy (first 6 months)
Study: 8828422
Drug: Resumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resumption of hormone replacement therapy (after 6 months)
Study: 8828422
Drug: Suspension of
Normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension of hormone replacement therapy (after 6 months)
Study: 1448310
Drug: Miconazole oral
Normalized name: miconazole Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole oral gel
Study: 30644628
Drug: Intranasal 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 1.4 mg naloxone
Study: 30644628
Drug: Intramuscular 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 0.8 mg naloxone
Study: 30689736
Drug: Anti-PD-1 therapy
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 therapy (nivolumab)
Study: 26960919
Drug: Extubation failure
Normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extubation failure (adjusted for allocated treatment)
Study: 22735801
Drug: Intravitreal Triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Triamcinolone Acetonide (4 mg)
Study: 22735801
Drug: Intravitreal Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Bevacizumab (1.25 mg)
Study: 10338904
Drug: Salmeterol aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol aerosol 42 micrograms twice daily
Study: 10338904
Drug: Placebo (as‐needed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (as‐needed albuterol)
Study: 8275438
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg gabexate mesilate, intravenously twice a day for 5 days after TAE
Study: 8275438
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg gabexate mesilate
Study: 2498383
Drug: 4-hour continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-hour continuous intravenous infusion of GH (180-micrograms bolus dose, then 3 micrograms/min)
Study: 2498383
Drug: 6-hour continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-hour continuous intravenous infusion of GH (180-micrograms bolus dose, then 3 micrograms/min)
Study: 17067136
Drug: Magnesium 40
Normalized name: Magnesium 400mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium 40 mg x kg(‐1) for 5 min at 6.5 min before induction
Study: 17067136
Drug: Vecuronium 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.02 mg x kg(‐1) at 1.5 min before induction
Study: 17067136
Drug: Saline 1-2
Normalized name: NS-2
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 1-2 ml at 1.5 min before induction
Study: 8551420
Drug: Reduced osmolarity
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced osmolarity ORS (245 mmol/L sodium and glucose)
Study: 8551420
Drug: Standard WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard WHO ORS (311 mmol/L)
Study: 6882881
Drug: Experimental ASA
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental ASA formulation
Study: 30132262
Drug: Metformin (850-1700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850-1700 mg)
Study: 29980120
Drug: Present Centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present Centered Group Therapy (PCGT)
Study: 21603629
Drug: Artesunate 2
Normalized name: Artesunate 25 mg and mefloquine (as mefloquine hydrochloride) 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate 2 mg/kg/day
Study: 21603629
Drug: Artesunate 4
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate 4 mg/kg/day
Study: 21603629
Drug: Artesunate 6
Normalized name: artesunate 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate 6 mg/kg/day
Study: 19000552
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 25 mg pactimibe
Study: 19000552
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 100 mg pactimibe for 21 days in CYP2D6 PMs
Study: 9332112
Drug: Intravenous Magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Magnesium sulfate (0.2 ml/kg of 50% MgSO4 as intravenous infusion over 35 minutes)
Study: 9332112
Drug: Intravenous Magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Magnesium sulfate
Study: 9332112
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline infusion in the same dose and at the same rate)
Study: 8441894
Drug: Lozenges
Normalized name: Zinc Lozenges
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lozenges
Study: 3741825
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine (1.5 mg kg‐1)